DYN

15.4603.56%
DC

David Charles Lubner

Independent Director

Mr. David Charles Lubner, C.P.A., M.S., is Treasurer, Secretary & Director of Cerevance, LLC. He serves as an Independent Director since June 2026 at Kinaset Therapeutics. Mr. Lubner is Director of Braveheart Bio, Inc. from June 2026. He serves as Director at Secretome Therapeutics, Inc. from May 2026. Mr. Lubner was Director of Cerevance, LLC from December 2020. Mr. Lubner is Independent Director of Crescent Biopharma, Inc. from April 2025. He is Advisor at RA Capital Management, L.P. Mr. Lubner served as Venture Partner of RA Capital Management, L.P. from 2023 till 2026. He was Director at Be Biopharma, Inc. since 2022. He served as Independent Director of CARGO Therapeutics, Inc. since July 2023 until August 18, 2025. Mr. Lubner is Independent Director at POINT Biopharma Global Inc. since May 2020. He has been Director at Cerevance LLC since December 2020. Mr. Lubner had been an Independent Director of Vor Biopharma Inc. since July 2020 until August 26, 2025 and serves as Independent Director at ProScript Therapeutics, Inc. since March 2020. He had been Director of Therapeutics Acquisition Corp. since May 2020 until June 2021. He served as Chief Financial Officer and Executive Vice President at Ra Pharmaceuticals, Inc. since January 11, 2016 until June 2020 and served as its Secretary. Mr. Lubner serves as a Financial Consultant of Mediphase Venture Partners. Mr. Lubner served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. from its inception in 2006 to January 2016, including as Senior Vice President and Chief Financial Officer from 2006 to 2016. He served as Chief Operating Officer of Tetraphase Pharmaceuticals, Inc. from 2006 to October 2010. He joined Mediphase Venture Partners in 2006. He has financial and leadership experience as a senior executive in the biotechnology industry and experience as a director of a public biotechnology company. He served as the Chief Financial Officer of PharMetrics, Inc. from 1999 to 2015 and managed its successful acquisition by IMS Health. He served as a Vice President of Finance and Vice President of Administration at PharMetrics, Inc. He has served as a member of RACA board of directors since May 2020. He served as the Chief Financial Officer and Vice President at ProScript, Inc. from 1996 to 1999. His responsibilities included finance and administration, business development and mergers and acquisitions. He has been Chairman of the Board of Directors of Gemini Theraputics, Inc. He had been an Independent Director of Gemini Therapeutics, Inc. (formerly known as FS Development Corp.) since April 2020 until December 2021 and Ichnos Sciences, Inc. David Lubner. David C. Lubner, M.S. has served as a director of our company since August 2020. Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals Inc., a biotechnology company acquired by UCB S.A. in April 2020, from January 2016 until June 2020. Before joining Ra Pharmaceuticals, Mr. Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals from its inception in 2006 to 2016, as Chief Financial Officer of PharMetrics from 1999 until it was acquired by IMS Health in 2005 and as Vice President and Chief Financial Officer of ProScript from 1996 to 1999, where Velcade ® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered. Mr. Lubner serves as a member of the board of directors of Dyne Therapeutics Inc. (Nasdaq: DYN), Crescent Biopharma (Nasdaq: CBIO) and several other private companies. Mr. Lubner served on the board of directors of Point Biopharma Global, Inc. from 2021 until it was acquired by Eli Lilly & Co. in December 2023. He was an Independent Director of Arcellx, Inc. since August 2020 until April 28, 2026. He also served as a Controller at Immulogic Pharmaceutical Corp. from 2020 to 2022. He served as Non-Executive Director of Nightstar Therapeutics Limited since July 13, 2017 until June 07, 2019. Mr. Lubner has been a Director of NightstaRx Limited since July 13, 2017. Mr. Lubner has been an Independent Director of Dyne Therapeutics, Inc. since March 2020. Mr. Lubner is also a member of the American Institute of Certified Public Accountants and is a certified public accountant in Massachusetts. He received his B.S. in Business Administration and Accounting from Northeastern University and an M.S. in taxation from Bentley University.

Positions